Trial Profile
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Zoledronic acid
- Indications Bone metastases; Lymphoma; Multiple myeloma; Non-small cell lung cancer; Small cell lung cancer; Solid tumours
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
- 01 Mar 2021 Results (n=302) of post hoc analysis identifying the risk factors of Skeletal related events in patients with bone metastasis from NSCLC, published in the Supportive Care in Cancer
- 19 Nov 2020 According to a BeiGene media release, the approval of XGEVA for the prevention of skeletal-related events (SREs) in patients with bone metastasis from solid tumors and MM was based on clinical results from four randomized international trials (NCT00321464, NCT00330759, NCT00321620, and NCT01345019).
- 19 Nov 2020 According to a BeiGene media release, the China National Medical Products Administration (NMPA) has approved XGEVA (denosumab) for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors and in patients with multiple myeloma (MM).